<DOC>
	<DOCNO>NCT03046992</DOCNO>
	<brief_summary>YH25448 oral , highly potent , mutant-selective irreversible EGFR Tyrosine-kinase inhibitor ( TKIs ) target T790M mutation activate EGFR mutation spar wild type-EGFR . YH25448 expect beneficial NSCLC patient brain metastasis due good blood brain barrier ( BBB ) penetration property well treatment primary lung lesion extracranial lesion . This study conduct evaluate safety , tolerability efficacy YH25448 locally advance metastatic NSCLC patient EGFR mutation .</brief_summary>
	<brief_title>Clinical Trial YH25448 Patients With EGFR Mutation Positive Advanced NSCLC</brief_title>
	<detailed_description>This first time patient study primarily design evaluate safety , tolerability , efficacy YH25448 patient EGFR mutation positive ( EGFRm+ ) advance NSCLC without asymptomatic brain metastasis progress follow prior therapy EGFR TKIs agent . This study compose 3 part ; part A dose escalation phase , part B dose expansion phase part C dose extension phase . In dose escalation phase , YH25448 escalate reach either maximum tolerate absorbable dose patient define dose-limiting toxicity NSCLC patient progress follow prior EGFR TKIs treatment evaluate safety tolerability . In dose expansion phase , safety , tolerability , pharmacokinetic ( PK ) efficacy evaluate dose level ( ) dose escalation phase NSCLC patient progress follow prior EGFR TKIs treatment harbour confirm T790M mutation . In dose extension phase , additional 3 cohort ( 2nd line therapy cohort , 1st line therapy cohort , brain metastasis cohort ) enrol assess efficacy , safety , tolerability , PK YH25448 maximum tolerate dose ( MTD ) recommend dose ( RD ) define dose escalation phase dose expansion phase . Results study serve evidence clinical development . This study also characterize metabolite ( ) profile YH25448 determine PK metabolite ( ) biological sample necessary . Also , exploratory correlation biomarker profile pharmacokinetics/pharmacodynamics analyze .</detailed_description>
	<criteria>Histologically cytologically confirm diagnosis NSCLC single activate EGFR mutation . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 deterioration previous 2 week minimum life expectancy 3 month . At least one measurable extracranial lesion , previously irradiate chosen biopsy study screen period . Prior enrol study , patient must central confirmation T790M+ mutation status sample take documented progression EGFRTKIs therapy accord cohort . Spinal cord compression . Brain metastases symptomatic and/or require steroid least 2 week prior start study treatment . Known intracranial hemorrhage unrelated tumor . Central Nervous System ( CNS ) complication require urgent neurosurgical intervention ( e.g . resection shunt placement ) . Leptomeningeal metastasis prior study treatment . Past medical history interstitial lung disease ( ILD ) , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD . Any cardiovascular disease follow . History symptomatic congestive heart failure ( CHF ) serious cardiac arrhythmia require treatment History myocardial infarction unstable angina within 6 month first dose study treatment Left ventricular ejection fraction ( LVEF ) &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EGFR</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>T790M</keyword>
	<keyword>Brain Metastasis</keyword>
</DOC>